Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Authors: Enriqueta Felip, Nasser Altorki, Caicun Zhou, Eric Vallières, Tibor Csoszi, Ihor O. Vynnychenko, Oleksandr Goloborodko, Achim Rittmeyer, Martin Reck, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, Chenqi Fu, Marcus Ballinger, Yu Deng, Minu K. Srivastava, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee,

Published: 2025-05-30

DOI: 10.1200/jco-24-01681

Source: Full article

---

Abstract

IMpower010 (ClinicalTrials.gov identifier: